An Observational Study on the Use of Immune Checkpoint Inhibitors Combined with Cetuximab and Chemotherapy in the Later Lines of Treatment for Advanced Colorectal Cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500097178

Enrollment

Unknown

Registered

2025-02-13

Start date

2025-02-28

Completion date

Unknown

Last updated

2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

Combination of immunotherapy, cetuximab and chemotherapy:None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: a) Adult patients with advanced colorectal cancer (aged at least 18 years old at the time of enrollment). b) Patients with histologically confirmed RAS wild-type colorectal cancer in the past, who have failed at least two lines of systemic treatment and have received the combination of immune checkpoint inhibitors, cetuximab and chemotherapy in the third-line treatment or subsequent treatments.

Exclusion criteria

Exclusion criteria: a) The patient is simultaneously participating in another study involving investigational drugs and/or interventions.

Design outcomes

Primary

Measure	Time frame
Objective Response Rate;Disease Control Rate;Progression-Free Survival;Overall Survival;	—

Secondary

Measure	Time frame
Incidence rate of adverse reactions;	—

Countries

China

Contacts

Public ContactTianshu Liu

Zhongshan Hospital Affiliated to Fudan University

liutianshu1969@126.com+86 136 8197 3996

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026